相似文献
1
A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes.
Cancer Cell. 2006 Nov;10(5):425-35. doi: 10.1016/j.ccr.2006.09.014.
2
Systems biology modeling reveals a possible mechanism of the tumor cell death upon oncogene inactivation in EGFR addicted cancers.
PLoS One. 2011;6(12):e28930. doi: 10.1371/journal.pone.0028930. Epub 2011 Dec 14.
3
Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Oncogene. 2002 Nov 21;21(53):8075-88. doi: 10.1038/sj.onc.1206008.
4
"Oncogenic shock": explaining oncogene addiction through differential signal attenuation.
Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4392s-4395s. doi: 10.1158/1078-0432.CCR-06-0096.
5
Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.
Breast Cancer Res. 2011 Sep 17;13(5):R89. doi: 10.1186/bcr2946.
6
Survival and death signals can predict tumor response to therapy after oncogene inactivation.
Sci Transl Med. 2011 Oct 5;3(103):103ra99. doi: 10.1126/scitranslmed.3002018.
7
Potentiation of epidermal growth factor-mediated oncogenic transformation by sialidase NEU3 leading to Src activation.
PLoS One. 2015 Mar 24;10(3):e0120578. doi: 10.1371/journal.pone.0120578. eCollection 2015.
8
Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Cancer Biol Ther. 2012 Nov;13(13):1244-54. doi: 10.4161/cbt.21460. Epub 2012 Aug 16.
9
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.
Oncogene. 2001 May 3;20(20):2499-513. doi: 10.1038/sj.onc.1204349.
10
The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and {beta}-arrestin1-dependent signaling pathways.
J Biol Chem. 2010 Dec 17;285(51):39672-81. doi: 10.1074/jbc.M110.117689. Epub 2010 Oct 19.
引用本文的文献
1
Emerging AXL Inhibitors in Oncology: Chemical and Biological Advances in Targeted Cancer Therapy.
Anticancer Agents Med Chem. 2025;25(7):460-467. doi: 10.2174/0118715206351185241209053053.
2
4″-Alkyl EGCG Derivatives Induce Cytoprotective Autophagy Response by Inhibiting EGFR in Glioblastoma Cells.
ACS Omega. 2024 Jan 3;9(2):2286-2301. doi: 10.1021/acsomega.3c06110. eCollection 2024 Jan 16.
3
Study of Strawberry Notch homolog 1 and 2 expression in human glioblastoma.
J Neurooncol. 2023 Feb;161(3):515-523. doi: 10.1007/s11060-023-04240-7. Epub 2023 Jan 25.
4
An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies.
Cell Mol Life Sci. 2022 Dec 10;80(1):6. doi: 10.1007/s00018-022-04634-2.
5
Cinobufagin Exerts Anticancer Activity in Oral Squamous Cell Carcinoma Cells through Downregulation of ANO1.
Int J Mol Sci. 2021 Nov 7;22(21):12037. doi: 10.3390/ijms222112037.
6
Gelatin methacrylate hydrogels culture model for glioblastoma cells enriches for mesenchymal-like state and models interactions with immune cells.
Sci Rep. 2021 Sep 6;11(1):17727. doi: 10.1038/s41598-021-97059-z.
7
Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia.
Leukemia. 2020 Oct;34(10):2635-2647. doi: 10.1038/s41375-020-0977-8. Epub 2020 Jul 20.
8
Epidermal growth factor receptor first generation tyrosine-kinase inhibitors.
Transl Lung Cancer Res. 2019 Nov;8(Suppl 3):S235-S246. doi: 10.21037/tlcr.2019.04.20.
9
CRISPR/Cas9-mediated gene deletion efficiently retards the progression of Philadelphia-positive acute lymphoblastic leukemia in a p210 BCR-ABL1 mutation mouse model.
Haematologica. 2020 May;105(5):e232-e236. doi: 10.3324/haematol.2019.229013. Epub 2019 Sep 19.
10
Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells.
Elife. 2018 Nov 26;7:e33718. doi: 10.7554/eLife.33718.
本文引用的文献
1
"Oncogenic shock": explaining oncogene addiction through differential signal attenuation.
Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4392s-4395s. doi: 10.1158/1078-0432.CCR-06-0096.
2
Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.
Cancer Res. 2005 Oct 1;65(19):8968-74. doi: 10.1158/0008-5472.CAN-05-1829.
3
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94. doi: 10.1093/jnci/dji238.
4
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11. doi: 10.1073/pnas.0405220101. Epub 2004 Aug 25.
5
Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells.
Blood. 2004 Oct 15;104(8):2514-22. doi: 10.1182/blood-2003-11-4065. Epub 2004 Jun 29.
6
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. Epub 2004 Apr 29.
7
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
8
9
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.
Leukemia. 2004 Feb;18(2):189-218. doi: 10.1038/sj.leu.2403241.
10
Janus faces of ras: anti or pro-apoptotic?
Apoptosis. 1999 Oct;4(5):383-8. doi: 10.1023/a:1009651406017.
Zotero 插件